Skip to main content

Advertisement

SpringerLink
Log in

Factors affecting the effectiveness of intravesical injection of botulinum toxin A in females with overactive bladder

  • Original Article
  • Published:
Journal of Inclusion Phenomena and Macrocyclic Chemistry Aims and scope Submit manuscript

Abstract

The objective of this study is to examine the determinants influencing the efficacy of intravesical administration of botulinum toxin A (BoNT-A) in patients suffering from overactive bladder (OAB). The study included 32 females diagnosed with OAB, with or without urge urinary incontinence. All participants underwent BoNT-A injections (100 units) at the posterior bladder wall (20 points) from our institution between March 2017 and June 2020. Clinical data was gathered, and the severity of OAB was evaluated both before and four weeks following the procedure utilizing the International Consultation on Incontinence Modular Questionnaire-Urinary Incontinence (ICIG-UI) and the Overactive Bladder Symptom Score (OABSS). The study also looked into the status of medication for OAB four weeks after the procedure. Total mean ICIQ-UI and OABSS were significantly improved four weeks after BoNT-A injection (14.00 ± 3.46 to 7.00 ± 6.82, p < 0.001 and 11.40 ± 5.01 to 6.40 ± 1.25, p = 0.009, respectively). Younger age, longer OAB duration, and ongoing OAB medication were the factors that significantly improved the effectiveness of BoNT-A injection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

No datasets were generated or analysed during the current study.

References

  1. Abrams, P., Cardozo, L., Griffiths, D., Rosier, P., Ulmsten, U., van Kerrebroeck, P., Victor, A., Wein, A.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21, 167–178 (2002)

    Article  PubMed  Google Scholar 

  2. Chapple, C.R.: Muscarinic receptor antagonist in the treatment of overactive bladder. Urology 55, 33–50 (2000)

    Article  CAS  PubMed  Google Scholar 

  3. Hsiao, S.-M., Lin, H.-H., Kuo, H.-C.: Factors associated with therapeutic efficacy of intravesical onabotulinum toxin A injection for overactive bladder syndrome. PLoS One 29, e0147137. (2016). https://doi.org/10.1371/journal.pone.0147137

    Article  CAS  Google Scholar 

  4. Kuo, H.C.: Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 63, 868–872 (2004)

    Article  PubMed  Google Scholar 

  5. Sahai, A., Khan, M.S., Dasgupta, P.: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: Results from a single center, randomized, double-blind, placebo controlled trial. J. Urol. 177, 2231–2236 (2007)

    Article  CAS  PubMed  Google Scholar 

  6. Brubaker, L., Richter, H.E., Visco, A., Mahajan, S., Nygaard, I., Braun, T.M., Barber, M.D., Menefee, S., Schaffer, J., Weber, A.M., Wei, J.: Refractory idiopathic urge urinary incontinence and botulinum A injection. J. Urol. 180, 217–222 (2008)

    Article  PubMed  PubMed Central  Google Scholar 

  7. Popat, R., Apostolidis, A., Kalsi, V., Gonzales, G., Fowler, C.J., Dasgupta, P.: Comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J. Urol. 174, 984–989 (2005)

    Article  CAS  PubMed  Google Scholar 

  8. Rajkumar, G.N., Small, D.R., Mustafa, A.W., Conn, G.: A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int. 96, 848–852 (2005)

    Article  CAS  PubMed  Google Scholar 

  9. Kessler, T.M., Danuser, H., Schumacher, M., Studer, U.E., Burkhard, F.C.: Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol. Urodyn. 24, 231–236 (2005)

    Article  CAS  PubMed  Google Scholar 

  10. Werner, M., Schmid, D.M., Schussler, B.: Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am. J. Obstet. Gynecol. 192, 1735–1740 (2005)

    Article  CAS  PubMed  Google Scholar 

  11. Kuo, H.C.: Clinical effects of suburothelial injection of botulinum A toxin in patients with non-neurogenic detrusor overactivity refractory to anticholinergics. Urology 66, 94–98 (2005)

    Article  PubMed  Google Scholar 

  12. Schiavo, G., Santucci, A., DasGupta, B.R., Mehta, P.P., Jontes, J., Benfenati, F., Wilson, M.C., Montecucco, C.: Botulinum neurotoxins serotypes A and E cleave Snap-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 335, 99 (1993)

    Article  CAS  PubMed  Google Scholar 

  13. Franciosa, G., Floridi, F., Maugliani, A., Aureli, P.: Differentiation of the gene clusters encoding botulinum neurotoxin type A complexes in Clostridium botulinum type A, Ab, and A(B) strains. Appl. Environ. Microbiol. 70, 7192–7199 (2004)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Dolly, J.O., Oonnell, M.A.: Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr. Opin. Pharmacol. 12, 100–108 (2012)

    Article  CAS  PubMed  Google Scholar 

  15. Rummel, A.: The long journey of botulinum neurotoxins into the synapse. Toxicon 107, 9–24 (2015)

    Article  CAS  PubMed  Google Scholar 

  16. Singh, B.R.: Intimate details of the most poisonous poison. Nat. Struct. Biol. 7, 617–619 (2000)

    Article  CAS  PubMed  Google Scholar 

  17. Dong, M., Yeh, F., Tepp, W.H., Dean, C., Johnson, E.A., Janz, R., Chapman, E.R.: SV2 is the protein receptor for botulinum neurotoxin A. Science 312, 592–596 (2006)

    Article  CAS  PubMed  Google Scholar 

  18. Gu, H.-Y., Song, J.-K., Zhang, W.-J., Xie, J., Yao, Q.-S., Zeng, W.-J., Zhang, C., Niu, Y.-M.: A systematic review and meta-analysis of effectiveness and safety of therapy for overactive bladder using botulinum toxin A at different dosages. Oncotarget 8, 90338–90350 (2017)

    Article  PubMed  PubMed Central  Google Scholar 

  19. Malde, S., Fry, C., Schurch, B., Marcelissen, T., Averbeck, M., Digesu, A., Sahai, A.: What is the exact working mechanism of botulinum toxin A and sacral nerve stimulation in the treatment of overactive bladder/detrusor overactivity? ICI-RS 2017. Neurourol. Urodyn. 37, S108–S116 (2018)

    Article  PubMed  Google Scholar 

  20. Lawrence, G.W., Aoki, K.R., Dolly, J.O.: Excitatory cholinergic and purinergic signaling in bladder are equally susceptible to botulinum neurotoxin a consistent with co-release of transmitters from efferent fibers. J. Pharmacol. Exp. Ther. 334, 1080–1086 (2010)

    Article  CAS  PubMed  Google Scholar 

  21. Birder, L.A., Andersson, K.E., Kanai, A.J., Hanna-Mitchell, A.T., Fry, C.H.: Urothelial mucosal signaling and the overactive bladder-ICI-RS 2013. Neurourol. Urodyn. 33, 597–601 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hanna-Mitchell, A.T., Kashyap, M., Chan, W.V., Andersson, K.-E., Tannenbaum, C.: Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013. Neurourol. Urodyn. 33, 611–617 (2014)

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. RS-2023-00277502).

Funding

This work was funded by National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (Grant No. RS-2023-00277502).

Author information

Authors and Affiliations

  1. Department of Urology, Pusan National University Hospital, 179 Gudeok-Ro, Seo-Gu, Busan, 49241, South Korea

    Kyoungha Jang, Dong Gil Shin, Wooseop Seong, Seunghyeon Kim, Tae Nam Kim, Jeong Zoo Lee & Hyeon Woo Kim

  2. Department of Urology, Pusan National University School of Medicine, 179 Gudeok-Ro, Seo-Gu, Busan, 49241, South Korea

    Dong Gil Shin, Tae Nam Kim, Jeong Zoo Lee & Hyeon Woo Kim

  3. Department of Mechatronics Engineering, Chonnam National University, 50 Daehak-Ro, Yeosu, Jeonnam, 59626, South Korea

    Yangkyu Park

Authors
  1. Kyoungha Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong Gil Shin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wooseop Seong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seunghyeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tae Nam Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jeong Zoo Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yangkyu Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hyeon Woo Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dong Gil Shin wrote the main manuscript text. Kyoungha Jang has collected the whole data and assisted in writing the main manuscript text. Wooseop Seong and Seunghyeon Kim prepared Figs. 1 and 2. Tae Nam Kim and Jeong Zoo Lee prepared Tables 1 and 2. Yangkyu Park has conducted statistical analysis. Hyeon Woo Kim has supervised the whole manuscript process. All authors reviewed the manuscript.

Corresponding author

Correspondence to Hyeon Woo Kim.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of interest

The authors declare no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Dong Gil shin is the first author of this manuscript.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jang, K., Shin, D.G., Seong, W. et al. Factors affecting the effectiveness of intravesical injection of botulinum toxin A in females with overactive bladder. J Incl Phenom Macrocycl Chem (2024). https://doi.org/10.1007/s10847-024-01236-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10847-024-01236-2

Keywords

Search

Navigation